Sunday, August 26, 2012

Breast cancer risk after supradiaphragmatic radiotherapy persists beyond 40 years

******
******
Everything...and I mean EVERYTHING comes with a price tag.

I came upon this, and my breath caught. This has nothing to do with my personal health journey. It has everything, however, to do with dear sweet 16 year old Hannah...just another potential battle you may have to face down the road. Hannah was diagnosed with Hodgkin's Lymphoma this past spring when she was 15, and has been undergoing very aggressive treatment since. Her last round is scheduled for erev Rosh Hashanah. Her mother (Andrea), whom I got to shared a hug with this past Thursday, was looking at the poetic and positive portend associated with this timing.  Andrea has always been a 1/2 glass full lady.

I, on the other hand, have been trained to be the consummate cynic (4.5 years of law school and nearly two decades practicing law). I listen to the treatment regimen Hannah's young body has had to endure these past six months; I recall my own fears of cumulative radiation exposure;  I stumble across the following abstract; and I viscerally cringe.

And, again, I ask the question constantly on my lips - why must anyone sacrifice their long term health as the cost of being "cured" today?  ####


1:35 | Jun 29, 2012 | Oncology, Reuters Health • The Doctor's Channel Daily Newscast, Women’s Health


NEW YORK (Reuters Health) – The increased risk of breast cancer in women who received radiotherapy above the diaphragm for treatment of Hodgkin’s lymphoma (HL) persists for at least 40 years after treatment, according to a national cohort study from the United Kingdom.

These women need to be followed for at least 40 years, perhaps with more-intensive screening regimens, say the investigators from the England and Wales Hodgkin Lymphoma Follow-Up Group in a report online June 25 in the Journal of Clinical Oncology.

“Supradiaphragmatic radiotherapy is still widely used although techniques and doses keep changing,” first author Dr. Anthony J. Swerdlow, from the Institute of Cancer Research, Sutton, Surrey, England, commented in an email to Reuters Health.

He and his colleagues documented the clinical characteristics, treatment, and subsequent outcomes of 5,002 women with HL treated with supradiaphragmatic radiation (mantle-field in two thirds of the population) in England and Wales from 1956 to 2003. The women were younger than 36 at the time of treatment and were followed through the end of 2008.

The researchers used modeling to describe specific, cumulative breast cancer risk at given time points during follow-up according to age at diagnosis, treatment type (inclusion of alkylating agents or pelvic radiation), radiation dose, and time from first treatment.

A total of 373 women developed breast cancer or ductal carcinoma in situ during follow up, yielding a standardized incidence ratio (SIR) of 5.0.

SIRs were greatest for those treated at age 14 years (47.2) and “continued to remain high for at least 40 years. The maximum absolute excess risk was at attained ages 50 to 59 years,” the investigators report. Alkylating chemotherapy or pelvic radiotherapy diminished the risk, but only for women treated at age 20 or older, not for those treated when younger.

The authors tabulated “in detail” cumulative risks of breast cancer based on various factors. For example, the cumulative risk of breast cancer in a woman 20 to 24 years old at the time of treatment with supradiaphragmatic radiation is 3.5% at 20 years and 29.2% at 40 years. For those treated with supradiaphragmatic radiation plus alkylating chemo and/or pelvic radiotherapy, the corresponding risks are 3.6% and 11.5%.

“I think the clinical implications (of the article) are in the provision of risk statistics to use to advise patients,” Dr. Swerdlow said.

In an accompanying commentary, Dr. Michael Crump, from Princess Margaret Hospital and University of Toronto in Canada says, “The legacy of curative extended-field radiation for HL is a large survivor population that is at an increased lifetime risk of second cancer, in particular breast, lung and GI cancer. The article by Swerdlow et al … offers additional information to address the challenge of individual risk assessment.”

This is largest cohort of survivors of HL yet evaluated for breast cancer risk, Dr. Crump notes, and the results confirm those of others. Namely, that breast cancer risk is “highest in women treated with mantle radiotherapy around puberty, decreases with increasing age at treatment (although still elevated for women treated in their thirties, the median age at diagnosis of HL in most countries), and decreases with smaller radiation field sizes and lower radiation doses. Gonadotoxic therapy (alkylating agents or radiation) reduced subsequent breast cancer risk but only for women treated after age 20 years.”

Dr. Swerdlow and colleagues say the “large cumulative risks of breast cancer we found 20 to 39 years after supradiaphragmatic radiotherapy, especially in patients treated at age 20 years, are similar to or higher than the risks by the same ages in BRCA1 and BRCA2 carriers. They suggest that intensive breast screening programs for such women may need to continue for 40 years and longer after initial radiotherapy.”

They also say their data showing maximum absolute excess risk at ages 50 to 59 years suggest that “more-intensive screening (eg, annual screening with magnetic resonance imaging) may be needed.”

In his editorial, Dr. Crump points out that “Both the American Cancer Society and the United Kingdom Notification Risk Assessment and Screening Programme recommend magnetic resonance imaging (MRI) as an adjunct to annual mammography for women who have received thoracic irradiation younger than age 36 years, starting 8 years after treatment. Available data suggest that efforts to enroll high-risk women onto screening programs are falling short, and less than half of women treated during adolescence or as young adults currently receive annual mammography.”

Continuing, Dr. Crump says, “The United Kingdom guideline recommends commencing screening at age 25 years but returns women to standard mammography once every three years once they have reached age 50 years. The report by Swerdlow et al suggests that this upper age limit should be reconsidered in light of the very high cumulative risk faced by women even beyond 30 years of follow-up,” he concludes.

SOURCE:

Toward Risk-Based Breast Cancer Screening and
Prevention Strategies for Survivors of Hodgkin’s
Lymphoma: One Step Closer?


Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin’s Lymphoma in England and Wales: A National Cohort Study

J Clin Oncol. 2012.

 

Wednesday, August 15, 2012

Random Musings...

******
******
In a society and culture myopically focused; stunted by an insatiable need for immediate gratification; and inexplicably driven to sacrifice reason for dogma.... "How [then] can we all get over ourselves long enough to really, truly notice other people? ~ Jeff Giles"

Friday, August 3, 2012

Overselling and Promoting Over Diagnosis...and the Winner is ?

******
******
Breast Cancer: Komen Oversells Mammograms, Doctors Say
abcnews.go.com
Medical Journal Column Calls Pink Charity Out for Bad Math

Two Dartmouth Medical School professors have called out Susan G. Komen for the Cure, accusing the pink-ribbon organization of overstating the benefits of mammograms in its advertisements.

The accusation comes about six months after the breast cancer charity came under fire for cutting Planned Parenthood funding, which it claimed was not a politically motivated decision. According to the foundation's most recent Form 990, it netted about $114 million in 2010.

The ad in question ran last October in several major magazines, and said, "The five-year survival rate for breast cancer when caught early is 98 percent." Its not. It's 23 percent."

"It sounds like you'd have to be crazy not to get screened. It sounds like a huge benefit," said Dr. Steven Woloshin, co-author of the article in BMJ, the British medical journal. "The statistic is totally distorted."

The problem is that a five-year survival rate is easy to manipulate, he said. The ad compares five-year survival rates for early-stage cancers and late-stage cancers, which Woloshin said is not a meaningful way to measure the benefits of screening. Here's why:

Suppose three women are diagnosed with breast cancer at age 67 when a doctor finds a small lump, and they die of the disease three years later, when they're 70. That five-year survival rate is a miserable zero percent because no one lived five years past their diagnosis dates.

Now, suppose the same women were diagnosed when they were 64 because the cancer showed up on mammograms, but they still die of breast cancer at age 70, he said. The new five-year survival rate is a triumphant 100 percent, even though the women actually survived cancer the same length of time. They just didn't know how long they had it.

"If there were an Oscar for misleading statistics, using survival statistics to judge the benefit of screening would win a lifetime achievement award hands down," Woloshin and his co-author Lisa Schwartz wrote.

More useful numbers, he said, are derived from randomized trials. They show that 0.53 percent of women in unscreened trial groups died over 10 years -- compared with 0.46 percent of the women who were screened. That's not much of a difference, the authors said.

This problem is further exacerbated by overdiagnosis, which happens when mammograms detect cancers that never grow or cause symptoms, he said.

For every woman saved by an early screening, two to 10 are falsely diagnosed, the authors wrote. This means patients endure biopsies, chemotherapy and radiation even though they don't have a threatening cancer.

"There's no way for an individual to know they've been overdiagnosed," Wolostin said, explaining that the only way to tell whether this has happened to a specific person is if that person is diagnosed, does not seek treatment and eventually dies of something else.

Doctors have seen evidence of overdiagnoses in long-term follow-ups to randomized trials and analyses of population data, he said.

In response to the article, Komen's Vice President of Research, Chandini Portteus, stood by the foundation's stance on mammograms, calling the screenings "the best widely available detection tool that we have today."

She said Komen has contributed funds toward even earlier detection.

"We think it's simply irresponsible to effectively discourage women from taking steps to know what's going on with their health," Portteus said, adding that the foundation is also funding research to determine which tumors will spread.

Woloshin said his article is not saying mammograms are bad.

"Some people benefit while other people are harmed," he said. "If you don't know, you can't make an informed decision."

####


What this article, as well as Komen do not express, is that mammograms can also be ineffective as a diagnostic tool. My form of b.c., invasive lobular - which started as a nearly imperceptible node, was consistently misdiagnosed as "fibrous breast tissue" for years before it grew to 6.2 cm and a biopsy followed by a MRI confirmed its true nature. My history of mammograms gave both my doctor and myself a false sense of health. Until the tumor insisted on recognition.

Additionally, this article and Komen do not address the cumulative nature of radiation - which is the energy behind mammograms; and our bodies inability to naturally purge this and all of the other daily exposures to radiation we encounter. All of which create a toxic environment within our bodies where cancer can happily proliferate.

I personally know many women who have been "diagnosed," via mammograms, with stage -0- / in-situ carcinoma (a pre-breast cancer state). With this diagnosis they have gone on, with full encouragement of their medical teams, to undergo the slash/burn/poison protocol. Their outcome: "cured." Yet, they all seem to be experiencing some after"gift" of their treatments -- no one should leave a party empty-handed. It begs the question: what were they actually cured of?

And, if they and their medical team had not relied so heavily on mammograms, would they have made a different choice?
                                                                                                    ~ TC

Tuesday, July 24, 2012

"Beauty Secrets" Revealed...Just Read the Label!

******
******

From: www.pronature.com


DANGEROUS BEAUTY: Scientists Warn of Harmful Ingredients In Our Shampoos and Cosmetics
~ by David Lowell Kern

Sodium Laurel Sulfate and Eye Damage in Young Children
The greatest concern of many scientists is sodium lauryl sulfate (SLS), a detergent found in about 90 percent of commercial shampoos. Also known as sodium dodecyl, sodium laureth sulfate (SLFS) this chemical has been shown to damage protein formation in eye tissue in young animals, raising serious concerns about the possibility of ocular tissue malformation, blindness in infants and young children. In animal studies, Sodium Laurel Sulfate penetration and uptake is much greater in neonatal and young animal eye tissue, compared to adult animals, showing "penetration into the eye, as well as systemic tissues (brain, heart, liver, etc.)" SLS also showed long-term retention in tissues, up to 5 days after a single drop.1

Researcher Keith Green, Ph.D., D. Sc., of the Medical College of Georgia, also reports that Sodium Laurel Sulfate extends the healing of corneal tissue by a factor of 5, from 2 days (normal) to more than 10 days. He also has concerns about cataract formation from Sodium Laurel Sulfate. Writing for Research to Prevent Blindness, Inc., Dr. Green states in part: There is an immediate concern relating to the penetration of these chemicals into the eye and other tissues. This is especially important in infants...exposure to SLS results in accumulation in eye tissues, a process that could retard healing and possibly have long-term effects. Dr. Green concludes that exposure to Sodium Laurel Sulfate sulfate causes improper eye development in children and that since Sodium Laurel Sulfate is absorbed systemically through the skin, it doesn't have to enter the eye directly.

Our own research found that SLS is present as a main ingredient in most commercial shampoos for adults or children.

Sodium Laurel Sulfate Toxicity and Cancer - Another serious health concern with SLS is its tendency to react with other ingredients to form NDELA, a nitrosamine and potent carcinogen. According to a 1978 FDA report, shampooing the hair with a product contaminated with this nitrosamine can lead to its absorption into the body at levels much higher than eating nitrate- contaminated foods. (Researchers estimate the nitrate absorption from one shampoo is equal to eating a pound of bacon.) The FDA has recently warned shampoo manufacturers of unacceptable levels of dioxin formation in products containing SLFS (dioxins are also dangerous carcinogenic compounds). Only laboratory testing can determine if a shampoo is contaminated with these powerful carcinogenic compounds.

Damage To Your Skin - Researchers have known for years that Sodium Laurel Sulfate is a skin irritant.

Sodium Laurel Sulfate is implicated in premature hair loss in men and women, and may be one reason for wide-spread incidence of thinning hair.

Sodium Laurel Sulfate is also implicated in scalp irritation, eczema, dandruff, and other scalp conditions. Many shampoos designed to alleviate dandruff, itching, and other scalp disorders may actually be causing the toxicity of Sodium Laurel Sulfate-containing formulas to the skin and scalp. Avoiding contact with this cytotoxic (cell- killing) chemical is all that many people require to completely alleviate scalp disorders.

Natural Brands Offer No Protection - Ingredient reviews of shampoos sold in health food stores under natural brands and labels have turned up many formulas containing Sodium Laurel Sulfate. The cost, reputation, or market position of a shampoo apparently has little to do with its contents. Some of the most reputable and exclusive brands contain Sodium Laurel Sulfate. Don't be fooled by high prices or marketing hype. You must check the ingredients on each product if you want to avoid the harmful effects of Sodium Laurel Sulfate.

References:

1. Clayton et. al., Ed. Chem. Tox., 1985
2. Br J Dermatol 1992 Sep
3. Contact Dermatitis 1992 Jul
4. Acta Derm Venereol (Stockh) 1991
5. Acta Derm Venereol Suppl (Stockh) 1992
6. The Lancet, Feb 3, 1990
7. Contact Dermatitis 1993 Sep
8. Contact Dermatitis 1993 Mar and 1993 Feb
9. Contact Dermatitis 1992 Sep
10. Journal of Toxicology, Cutaneous and Ocular Toxicology, 1992
11. Toxicology Letters, Vol 26, 1985
12. Toxicol Pathol 1992
13. Govt Reports Announcements & Index, 1993
14. Acta Derma Venereol (Stockh) 1992
15. Department of Dermatology, Rigshospitalet, Copenhagen


Here is list of ingredients to steer away from in our cosmetics and beauty products,and why. Unfortunately, due to the lax regulation in the U.S. the majority of these ingredients can be found in most of the products we use daily.

Alkylphenol Ethoxylates

Found to reduce sperm count

Benzene/Benzoic Acid/Benzyl Benzoate

Considered a carcinogen, is an endocrine disruptor, and is suspected to cause birth defects

Coal Tar

Known human carcinogen. Prohibited for us in cosmetics in the European Union. May contian harmful impurities or breakdown products. Found in dandruff shampoos, anti-itch creams and hair dyes.

Methyl, Propyl, Butyl and Ethyl Paraben

Used as inhibitors of microbial growth and to extend shelf life of products. Have caused many allergic reactions and skin rashes. Studies have shown that they are weakly estrogenic and can be absorbed by the body through the skin. Widely used even though they are known to be toxic.

Dibutyl Phthalate

Prohibited for us in cosmetics in the European Union. Possoble human reproductive or developmental toxin. Endocrine disruptor. Found in some nail polish, perfume and hair spray.

Diethanolamine (DEA), Triethanolamine (TEA)

Often used in cosmetics as emulsifiers and/or foaming agents. They can cause allergic reactions, eye irritation and dryness of hair and skin. DEA and TEA are "amines" (ammonia compounds) and can form cancer-causing nitrosamines when they come in contact with nitrates. Toxic if absorbed into the body over a long period of time. This chemical interferes with the body's ability to absorb choline which is needed for proper fetal brain development.

Diazolidinyl Urea, Imidazolidinyl Urea

These are widely used preservatives. The American Academy of Dermatology has found them to be a primary cause of contact dermatitis. Two trade names for these chemicals are Germall II and Germall 115. Neither of the Germall chemicals contains a good antifungal agent, and they must be combined with other preservatives. Both these chemicals release formaldehyde, which can be toxic.

Formaldehyde

This is an extreme irritant to the mucous membranes with often destructive effects. It is also considered to be a neurotoxin and carcinogen.

Fragrances

The label of "Fragrances" can mask a multitude of toxic, synthetic chemicals, many of which suppress the immune system, are endocrine disruptors, and cause cancer. When looking for scented products, make sure it's scented by essential oils -- which are expensive; therefore, companies usually list what essential oils are contained in the product without reverting to the generic term "Fragrances".

Isopropanol/Isopropyl Alcohol

This is a skin irritant that causes flushing, pulse rate fluctuations, dizziness, headaches, and nausea.

Lead Acetate

Known human reproductive and developmental toxin. Prohibited for use in cosmetics in the European Union. Found in some hair dyes and cleanser.

Mercury

Possible human carcinogen. Possible human reproductive or developmental toxin. Found in some eye drops and ointment.

Methylisothiazoline, or MIT

This can cause skin and eye irritation and is known to cause neurological damage.

Parabens (Isobutylparaben, Butylparaben, Methylparaben, Propylparaben)

Increases a person's risk of breast cancer. These class of chemicals are also endocrine disruptors and have been linked to fertility problems.

Petrolatum

Also known as petroleum jelly, this mineral oil derivative is used for its emollient properties in cosmetics. It has no nutrient value for the skin and can interfere with the body's own natural moisturizing mechanism, leading to dryness and chapping. It often creates the very conditions it claims to alleviate. Manufacturers use petrolatum because it is unbelievably cheap.

Petroleum Distillates

Possible human carcinogen. May contain harmful impurities or breakdown products. Prohibited for use in cosmetics in the European Union. Found in some mascara, perfume, foundation, lipstick and lip balm.

Phthalates

This has been linked to damage of the organs -- kidneys, lungs, and liver -- as well as the reproductive system.

Propylene Glycol

Ideally this is a vegetable glycerin mixed with grain alcohol, both of which are natural. Usually it is a synthetic petrochemical mix used as a humectant. It has been known to cause allergic reactions, hives and eczema. When you see PEG (polyethylene glycol) or PPG (polypropylene glycol) on labels, beware—these are related synthetics. Although exposure to high levels of Propylene Glycol is known to cause serious and potentially irreversible health conditions, the chemical industry tell us that "small" quantities or low level exposure of Propylene Glycol is "safe" to use on the skin and in food. According to the safety data sheets of industrial chemical manufacturers, chemicals such as Ethylene Glycol and Propylene Glycol will cause serious health conditions, including liver and heart damage and damage to the central nervous system if sufficient is absorbed by the body.

PVP/VA Copolymer

A petroleum-derived chemical used in hairsprays, styling aids and other cosmetics. It can be considered toxic, since inhaled particles can damage the lungs of sensitive persons.

Sodium Lauryl/Laureth Sulfate

A cheap, harsh detergent used in shampoos for its cleansing and foam-building properties. Often derived from petroleum, it is frequently disguised in pseudo-natural cosmetics with the phrase "comes from coconuts." It causes eye irritation, scalp scurf similar to dandruff, skin rashes and other allergic reactions. (See detailed report, above.)

Stearalkonium Chloride

A quaternary ammonium compound used in hair conditioners and creams. Developed by the fabric industry as a fabric softener, it is a lot cheaper and easier to use in hair conditioning formulas than proteins or herbals, which are beneficial to the hair. Causes allergic reactions. Toxic.

Synthetic Colors

Used to make cosmetics "pretty," synthetic colors, along with synthetic hair dyes, should be avoided at all costs. They will be labeled as FD&C or D&C, followed by a color and a number. Example: FD&C Red No. 6 / D&C Green No. 6. Many synthetic colors can be carcinogenic. If a cosmetic contains them, don't use it.

Synthetic Fragrances

The synthetic fragrances used in cosmetics can have as many as 200 ingredients. There is no way to know what the chemicals are, since on the label it will simply read "fragrance." Some problems caused by these chemicals include headaches, dizziness, rash, hyperpigmentation, violent coughing, vomiting, skin irritation—the list goes on. Advice: Don't buy a cosmetic that has the word "fragrance" on the ingredients label.

Friday, July 20, 2012

******
******

Stress Fuels Breast Cancer Metastasis to Bone

ScienceDaily (July 17, 2012) — Stress can promote breast cancer cell colonization of bone, Vanderbilt Center for Bone Biology investigators have discovered.

The studies, reported July 17 in PLoS Biology, demonstrate in mice that activation of the sympathetic nervous system -- the "fight-or-flight" response to stress -- primes the bone environment for breast cancer cell metastasis. The researchers were able to prevent breast cancer cell lesions in bone using propranolol, a cardiovascular medicine that inhibits sympathetic nervous system signals.

Metastasis -- the spread of cancer cells to distant organs, including bone -- is more likely to kill patients than a primary breast tumor, said Florent Elefteriou, Ph.D., director of the Vanderbilt Center for Bone Biology.

"Preventing metastasis is really the goal we want to achieve," he said.

Elefteriou and his colleagues knew from their previous studies that the sympathetic nervous system stimulated bone remodeling, and that it used some of the same signaling molecules that have been implicated in breast cancer metastasis to bone.

"We came to the hypothesis that sympathetic activation might remodel the bone environment and make it more favorable for cancer cells to metastasize there," Elefteriou said.

Evidence from the clinic supported this notion. Breast cancer patients who suffered from stress or depression following their primary treatment had shorter survival times. Both stress and depression activate the sympathetic nervous system.

To explore this possible link, the researchers studied cancer cell metastasis in mice. They followed fluorescently "tagged" human breast cancer cells that were injected into the mouse heart to model the stage of metastasis when breast cancer cells leave the primary site and move through the circulation.
They found that treating the mice with a drug that mimics sympathetic nervous system activation caused more cancer lesions in bone. Using physical restraint to stress the mice and activate the sympathetic nervous system also caused more cancer lesions in bone. Treating the restrained mice with propranolol, one of a family of blood pressure medicines called "beta-blockers," reduced the number of bone lesions.

The investigators demonstrated that sympathetic nervous system activation increases bone levels of a signaling molecule called RANKL, which is known to promote the formation of osteoclasts -- bone cells that break down bone tissue. RANKL has also been implicated in cell migration, and Elefteriou and colleagues were able to show that breast cancer cell migration to the bone depends on RANKL.
The findings suggest that beta-blockers or drugs that interfere with RANKL signaling, such as denosumab, may be useful in preventing breast cancer cell metastasis to bone. Propranolol and other beta-blockers are inexpensive, well characterized, and safe in most patients. They may be a good choice for long-term treatment if future studies in patients with breast cancer confirm their ability to block cancer cell metastasis to bone, Elefteriou said.

"If something as simple as a beta blocker could prevent cancer metastasis to bone, this would impact the treatment of millions of patients worldwide," he said.

Efforts to reduce stress and depression in patients with cancer may have unappreciated benefits in terms of metastasis prevention, he added